Hideki Shishido, PhD | American Lung Association

Location Select your location

Hideki Shishido, PhD

Research Awards Nationwide Recipient (2013-2015)

Oregon Health and Science University, Portland, OR
Developing New Method to Study Cystic Fibrosis Protein

Cystic fibrosis (CF) is a life-threatening inherited disease that primarily affects the lungs and digestive system of affected patients. In patients with CF, a protein called the cystic fibrosis transmembrane conductance regu-lator (CFTR) is malformed, causing the lungs to be susceptible to bacterial infections. An important goal of CF therapy is to understand how CFTR acquires its structure and to identify new therapies that assist in prevent-ing this malformation. Dr. Shishido and team are determined to develop an entirely new method to study how different regions of CFTR fold as they are synthesized in the cell. Results will hopefully provide a promising new approach for CF drug discovery that corrects the underlying molecular defect in CF patients.

Ask An Expert

Questions about your lung health? Need help finding healthcare? Call 1-800-LUNGUSA.

Get help
We need your generous support

Make a difference by delivering research, education and advocacy to those impacted by lung disease.

What is LUNG FORCE?

LUNG FORCE unites women and their loved ones across the country to stand together in the fight against lung cancer.

Get involved
Join the fight for healthy lungs and healthy air.
Donate Now.